• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
The ACTC-DS repository is under review for potential modification in compliance with Administration directives.
Alzheimer's Clinical Trials Consortium Down Syndrome

Alzheimer's Clinical Trials Consortium Down Syndrome

  • About Us
  • Projects
  • Sites
  • News
  • Alzheimer’s in Down Syndrome
  • Contact Us

Jeffrey L. Cummings, MD, ScD

October 1, 2019 by

Jeffrey L. Cummings, MD, ScD, is Chair of the ACTC Neuropsychiatric Symptoms Committee.

Dr. Cumming is Vice Chair of Research, UNLV Department of Brain Health. He is Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience.

Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.”

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.

Dr. Cummings has authored or edited 43 books and published over 750 peer-reviewed papers.

Gad Marshall, MD

October 1, 2019 by

Dr. Gad Marshall is board certified in Neurology, and is the Associate Medical Director of Clinical Trials at the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital; Associate Neurologist at Brigham and Women’s Hospital; Assistant in Neurology at Massachusetts General Hospital; and Associate Professor of Neurology at Harvard Medical School.

Dr. Marshall has served as site principal investigator for 13 Alzheimer’s disease clinical trials and 4 multicenter observational imaging biomarker studies, including currently the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 3, DoD-ADNI, and the Trial-Ready Cohort for Preclinical/Prodromal AD (TRC-PAD). He is the Brigham and Women’s Hospital Site Principal investigator, Steering Committee Member, and Chair of the Publications Committee for the Alzheimer’s Clinical Trial Consortium (ACTC).

His research has focused on clinical correlates of instrumental activities of daily living and neuropsychiatric symptoms with amyloid, tau, and FDG PET, structural and resting-state functional MRI, and CSF biomarkers across the early Alzheimer’s disease spectrum.

Christopher van Dyck, MD

October 1, 2019 by

Christopher van Dyck serves as Co-Chair for the Protocol Evaluation Committee (PEC) and a member of the Executive Committee for the ACTC. He is also Professor of Psychiatry, Neurology, and Neuroscience and Director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine.

Dr. van Dyck is a graduate of Yale College and Northwestern University Medical School. He completed his residency in psychiatry, fellowship in geriatric psychiatry, and research fellowship in neuroimaging before joining the faculty at Yale.

Dr. van Dyck is a recognized leader in the neuroimaging and therapeutics of Alzheimer’s disease and healthy aging. He is also Principal Investigator on grants from the National Institutes of Health, the pharmaceutical industry, and a number of private foundations and has authored more than 200 papers and reviews. Finally, Dr. van Dyck is extremely committed to advancing the cause of Alzheimer’s patients and their families on the local and national level. As Chairman of the Medical Scientific Advisory Committee for the Connecticut Chapter of the Alzheimer’s Association, he is intimately involved with local program development, advocacy, and education. He received the Alzheimer’s Association’s “Compassion and Cure” Award for 2005 and “Leader in Advancing Research” Award for 2017.

Bruno Vellas, MD

October 1, 2019 by

Bruno Vellas serves as Co-Chair for the ACTC Non-Pharmacological Interventions Committee. Dr. Vellas is the chair of the Gérontopôle & Department of Geriatric Internal Medicine at the Toulouse University Hospital and is member of INSERM UMR 1027. He studied medicine in Toulouse and received the degree of Doctor of Medicine in 1987 and a PhD in Pysiopathology in 1990. He had a doctoral training in nutrition and aging at the University of New Mexico, USA, Clinical Nutrition Lab, School of Medicine from 1987 to 1988. His main interests are: development of aging and geriatric clinical research and care. His research and care has been supported by several European, national and international research grants. He is the founder of the Gérontopôle to develop innovation and research for older adults. He is the author and co-author of more than 800 publications in peer review journals since 1987, Index H: 75. He serves as editor, editorial committee member and reviewer of several major journals. He is adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA and is member of the scientific advisory board of several major scientific institutions in France, EU, Japan and the US. Since 2016, he is titular member of the French National Academy of Medicine, Officier de la Légion d’Honneur, and was recipient of the Palmes Académiques in 2016. He is the past president of the IAGG (International Association of Gerontology and Geriatrics) a NGO with a seat at the United Nations, and the founder of the EADC (European Alzheimer’s Disease Consortium), the CTAD (Clinical Trial in Alzheimer’s Disease conference) and the ICFSR (International Conference for Frailty and Sarcopenia Research). He is the chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017. Lastly, Bruno VELLAS is Principal Investigator of the INSPIRE program in the field of Gerosciences.

Bradley Boeve, MD

October 1, 2019 by

Co-Chair, Non-AD Dementia Committee.

Dr. Boeve is a consultant in the Department of Neurology and Center for Sleep Medicine at Mayo Clinic in Rochester, Minnesota, and is Professor of Neurology in the Mayo Clinic College of Medicine and Science. He is recognized with the distinction of the Little Family Foundation Professorship in Lewy Body Dementia. He also serves as Chair of the Division of Behavioral Neurology. His clinical and research interests include MCI/AD as well as the non-Alzheimer’s degenerative dementias, with particular interests in the frontotemporal lobar degeneration-spectrum disorders (e.g., FTD+/-ALS, PPA, CBS, PSP) and Lewy body disease-spectrum disorders (e.g., DLB, PDD, RBD+MCI, and RBD). He is a member of the Medical Advisory Council of the Association for Frontotemporal Degeneration, the International Society for Frontotemporal Dementias, the FTD Prevention Initiative, the Scientific Advisory Council of the Lewy Body Dementia Association (LBDA), the LBDA Research Centers of Excellence Program, and International REM Sleep Behavior Disorder Study Group. He is co-PI or co-I on several national/international consortia focused on FTLD- and LBD-spectrum disorders. He is funded by the NIH, the Little Family Foundation, and the Mangurian Foundation.

Suzanne Craft, PhD

September 26, 2019 by

Suzanne Craft, PhD, is Co-Chair of the ACTC Site Metrics and Study Budgets Committee (SBSMC) and a Site Member PI on the ACTC Steering Committee.  She also serves on the Project Evaluation Committee and as a Site Member PI representative on the ACTC Executive Committee.  She is professor of Gerontology and Geriatric Medicine at Wake Forest University as well as at the Hypertension and Vascular Research Center.

Dr. Craft studied at the University of Texas – Austin and Interned at the VA Medical Center in Boston.  Her fellowships were in Neuropsychology at Boston University School of medical and Harvard medical school.  She is a member of the International Neuropsychological Society and the Society for Neuroscience.

Dr. Craft’s research has centered around Alzheimer’s disease, Cognition disorders, Dementia, Diet, Insulin and Insulin Resistance.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 11
  • Go to Next Page »

Primary Sidebar

Recent Comments

    Archives

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Categories

    • No categories

    Footer

    ACTC DS and NIA/NIH logos

    ACTC is funded by a Cooperative Agreement from the National Institute on Aging, National Institutes of Health.  Cooperative Agreement number U24AG057437.

    • About Us
    • Projects
    • Sites
    • News
    • Alzheimer’s in Down Syndrome
    • Contact Us
    • Privacy Policy
    • Terms of Use
    • California Privacy Rights
    Learn more about ACTC

    Copyright © USC ATRI 2026. All Rights Reserved.